What does the Reticulocyte Count and Reticulocyte Production Index test measure?

Why is Reticulocyte Count and Reticulocyte Production Index measured?

The reticulocyte count is the single most informative add-on to a CBC in anaemia evaluation — it immediately classifies anaemia as hyperproliferative (elevated reticulocytes, RPI ≥2: haemolysis or haemorrhage — the marrow is responding) or hypoproliferative (low or normal reticulocytes, RPI <2: nutritional deficiency, bone marrow failure, or anaemia of chronic disease — the marrow is not responding adequately). This classification is the pivotal second diagnostic step following MCV-based morphological classification and directs the subsequent investigation pathway. A rising reticulocyte count following iron, B12, or folate repletion therapy is the earliest objective evidence of treatment response — preceding haemoglobin improvement by 5–10 days.

Reference ranges

Standard reference

Reticulocyte count: 0.5–2.0%; Absolute reticulocyte count: 25–125 ×10³/µL; Reticulocyte Production Index (RPI): ≥2.0 (adequate marrow response) # REVIEWER FLAG: Confirm Access Medical Laboratories reference range for reticulocyte count and confirm whether they report absolute reticulocyte count and/or RPI as standard components of this panel. RPI calculation requires haematocrit input alongside the reticulocyte percentage — confirm whether this is automatically derived or requires manual calculation by the practitioner.

Functional medicine optimal

Absolute reticulocyte count: 40–100 ×10³/µL (functional medicine target for adequate but not excessive bone marrow erythropoietic output in a non-anaemic patient); RPI: ≥2.0 in the context of anaemia confirms an intact bone marrow compensatory response.

Units

% of RBC, Absolute: ×10³/µL

Reference ranges vary by laboratory and assay platform. Interpret in context of the issuing laboratory's stated range.